2016 - NANETS https://nanets.net/abstracts-archive/2016?format=html Thu, 15 Feb 2018 14:09:52 -0500 en-GB hourly 1 T03 – SPINET: A Randomized, Double-blind, Placebo-controlled Phase III Study of Lanreotide Autogel/Depot (LAN) in Patients with Advanced Lung Neuroendocrine Tumors https://nanets.net/abstracts-archive/2016/497-t03-spinet-a-randomized-double-blind-placebo-controlled-phase-iii-study-of-lanreotide-autogel-depot-lan-in-patients-with-advanced-lung-neuroendocrine-tumors?format=html T03 – SPINET: A Randomized, Double-blind, Placebo-controlled Phase III Study of Lanreotide Autogel/Depot (LAN) in Patients with Advanced Lung Neuroendocrine Tumors Reidy-Lagunes

 Download Poster

]]> https://nanets.net/abstracts-archive/2016/497-t03-spinet-a-randomized-double-blind-placebo-controlled-phase-iii-study-of-lanreotide-autogel-depot-lan-in-patients-with-advanced-lung-neuroendocrine-tumors?format=html Reidy-Lagunes

 Download Poster

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:09:52 -0500 T02 – A Phase II Trial of LEE011 in Combination with Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin https://nanets.net/abstracts-archive/2016/496-t02-a-phase-ii-trial-of-lee011-in-combination-with-everolimus-in-the-treatment-of-advanced-well-differentiated-neuroendocrine-tumors-of-foregut-origin?format=html T02 – A Phase II Trial of LEE011 in Combination with Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin Raj

]]> https://nanets.net/abstracts-archive/2016/496-t02-a-phase-ii-trial-of-lee011-in-combination-with-everolimus-in-the-treatment-of-advanced-well-differentiated-neuroendocrine-tumors-of-foregut-origin?format=html Raj

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:09:51 -0500 T01 – Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery https://nanets.net/abstracts-archive/2016/495-t01-cisplatin-and-etoposide-or-temozolomide-and-capecitabine-in-treating-patients-with-neuroendocrine-carcinoma-of-the-gastrointestinal-tract-or-pancreas-that-is-metastatic-or-cannot-be-removed-by-surgery?format=html T01 – Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery Eads

]]> https://nanets.net/abstracts-archive/2016/495-t01-cisplatin-and-etoposide-or-temozolomide-and-capecitabine-in-treating-patients-with-neuroendocrine-carcinoma-of-the-gastrointestinal-tract-or-pancreas-that-is-metastatic-or-cannot-be-removed-by-surgery?format=html Eads

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:09:50 -0500 O09 – Identifying and Prioritising Gaps in Neuroendocrine Tumour Researchresults of the Delphi Consensus Project of the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETS) https://nanets.net/abstracts-archive/2016/493-o09-identifying-and-prioritising-gaps-in-neuroendocrine-tumour-researchresults-of-the-delphi-consensus-project-of-the-commonwealth-neuroendocrine-tumour-research-collaboration-commnets?format=html O09 – Identifying and Prioritising Gaps in Neuroendocrine Tumour Researchresults of the Delphi Consensus Project of the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETS) Segelov

]]> https://nanets.net/abstracts-archive/2016/493-o09-identifying-and-prioritising-gaps-in-neuroendocrine-tumour-researchresults-of-the-delphi-consensus-project-of-the-commonwealth-neuroendocrine-tumour-research-collaboration-commnets?format=html Segelov

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:07:48 -0500 O10 – The Clinicopathologic Characteristics of Primary Presacral Neuroendocrine Tumor: A Single Center Experience https://nanets.net/abstracts-archive/2016/494-o10-the-clinicopathologic-characteristics-of-primary-presacral-neuroendocrine-tumor-a-single-center-experience?format=html O10 – The Clinicopathologic Characteristics of Primary Presacral Neuroendocrine Tumor: A Single Center Experience Yang

 Download Poster

]]> https://nanets.net/abstracts-archive/2016/494-o10-the-clinicopathologic-characteristics-of-primary-presacral-neuroendocrine-tumor-a-single-center-experience?format=html Yang

 Download Poster

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:07:48 -0500 O08 – Renal Neuroendocrine Tumors (rNETs): A Single-center Experience https://nanets.net/abstracts-archive/2016/492-o08-renal-neuroendocrine-tumors-rnets-a-single-center-experience?format=html O08 – Renal Neuroendocrine Tumors (rNETs): A Single-center Experience Scales

 Download Poster

]]> https://nanets.net/abstracts-archive/2016/492-o08-renal-neuroendocrine-tumors-rnets-a-single-center-experience?format=html Scales

 Download Poster

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:07:47 -0500 O07 – Antidepressant Use in Patients with Carcinoid Tumors: Results of A Systematic Review https://nanets.net/abstracts-archive/2016/491-o07-antidepressant-use-in-patients-with-carcinoid-tumors-results-of-a-systematic-review?format=html O07 – Antidepressant Use in Patients with Carcinoid Tumors: Results of A Systematic Review Isenberg-Grzeda

 Download Poster

]]> https://nanets.net/abstracts-archive/2016/491-o07-antidepressant-use-in-patients-with-carcinoid-tumors-results-of-a-systematic-review?format=html Isenberg-Grzeda

 Download Poster

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:07:46 -0500 O06 – Retrospective Chart Review of Antidepressant Use in Patients with Carcinoid Tumors https://nanets.net/abstracts-archive/2016/490-o06-retrospective-chart-review-of-antidepressant-use-in-patients-with-carcinoid-tumors?format=html O06 – Retrospective Chart Review of Antidepressant Use in Patients with Carcinoid Tumors Isenberg-Grzeda

 Download Poster

]]> https://nanets.net/abstracts-archive/2016/490-o06-retrospective-chart-review-of-antidepressant-use-in-patients-with-carcinoid-tumors?format=html Isenberg-Grzeda

 Download Poster

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:07:45 -0500 O04 – To Treat or Watch? Identifying Drivers of Decisions for Patients with GEPNET Using Reflective Multi-Criteria Decision Analysis https://nanets.net/abstracts-archive/2016/488-o04-to-treat-or-watch-identifying-drivers-of-decisions-for-patients-with-gepnet-using-reflective-multi-criteria-decision-analysis?format=html O04 – To Treat or Watch? Identifying Drivers of Decisions for Patients with GEPNET Using Reflective Multi-Criteria Decision Analysis Goetghebeur

]]> https://nanets.net/abstracts-archive/2016/488-o04-to-treat-or-watch-identifying-drivers-of-decisions-for-patients-with-gepnet-using-reflective-multi-criteria-decision-analysis?format=html Goetghebeur

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:07:44 -0500 O05 – A Case Series of 27 Primary Ovarian Neuroendocrine Tumors https://nanets.net/abstracts-archive/2016/489-o05-a-case-series-of-27-primary-ovarian-neuroendocrine-tumors?format=html O05 – A Case Series of 27 Primary Ovarian Neuroendocrine Tumors Heskel

]]> https://nanets.net/abstracts-archive/2016/489-o05-a-case-series-of-27-primary-ovarian-neuroendocrine-tumors?format=html Heskel

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:07:44 -0500 O03 – What Matters Most? An Exploration of Decision Criteria Considered by Patients with GEP-NET and Physicians Using Holistic Multi-Criteria Decision Analysis https://nanets.net/abstracts-archive/2016/487-o03-what-matters-most-an-exploration-of-decision-criteria-considered-by-patients-with-gep-net-and-physicians-using-holistic-multi-criteria-decision-analysis?format=html O03 – What Matters Most? An Exploration of Decision Criteria Considered by Patients with GEP-NET and Physicians Using Holistic Multi-Criteria Decision Analysis Goetghebeur

 Download Poster

]]> https://nanets.net/abstracts-archive/2016/487-o03-what-matters-most-an-exploration-of-decision-criteria-considered-by-patients-with-gep-net-and-physicians-using-holistic-multi-criteria-decision-analysis?format=html Goetghebeur

 Download Poster

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:07:43 -0500 O02 – Evidence of Improved Survival when Patients are Referred on to a Specialist NET Clinic with Multidisciplinary Team Management https://nanets.net/abstracts-archive/2016/486-o02-evidence-of-improved-survival-when-patients-are-referred-on-to-a-specialist-net-clinic-with-multidisciplinary-team-management?format=html O02 – Evidence of Improved Survival when Patients are Referred on to a Specialist NET Clinic with Multidisciplinary Team Management Ardill

]]> https://nanets.net/abstracts-archive/2016/486-o02-evidence-of-improved-survival-when-patients-are-referred-on-to-a-specialist-net-clinic-with-multidisciplinary-team-management?format=html Ardill

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:07:42 -0500 O01 – Addressing Neuroendocrine Tumour Related Emotional Issues https://nanets.net/abstracts-archive/2016/485-o01-addressing-neuroendocrine-tumour-related-emotional-issues?format=html O01 – Addressing Neuroendocrine Tumour Related Emotional Issues Ardill

]]> https://nanets.net/abstracts-archive/2016/485-o01-addressing-neuroendocrine-tumour-related-emotional-issues?format=html Ardill

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:07:41 -0500 C37 – Neoplasia in Patients with Atrophic Metaplastic Autoimmune Gastritis (AMAG): Screening and Surveillance Endoscopy Should Become Standard of Care https://nanets.net/abstracts-archive/2016/484-c37-neoplasia-in-patients-with-atrophic-metaplastic-autoimmune-gastritis-amag-screening-and-surveillance-endoscopy-should-become-standard-of-care?format=html C37 – Neoplasia in Patients with Atrophic Metaplastic Autoimmune Gastritis (AMAG): Screening and Surveillance Endoscopy Should Become Standard of Care Stashek

]]> https://nanets.net/abstracts-archive/2016/484-c37-neoplasia-in-patients-with-atrophic-metaplastic-autoimmune-gastritis-amag-screening-and-surveillance-endoscopy-should-become-standard-of-care?format=html Stashek

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:06:00 -0500 C35 – Liver Needle Biopsies are Poor Predictors of Histologic Tumor Grade for Midgut Neuroendocrine Tumors https://nanets.net/abstracts-archive/2016/482-c35-liver-needle-biopsies-are-poor-predictors-of-histologic-tumor-grade-for-midgut-neuroendocrine-tumors?format=html C35 – Liver Needle Biopsies are Poor Predictors of Histologic Tumor Grade for Midgut Neuroendocrine Tumors Ramirez

]]> https://nanets.net/abstracts-archive/2016/482-c35-liver-needle-biopsies-are-poor-predictors-of-histologic-tumor-grade-for-midgut-neuroendocrine-tumors?format=html Ramirez

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:05:59 -0500 C36 – Outcomes for Patients with Surgically Resected Thymic Neuroendocrine Tumors https://nanets.net/abstracts-archive/2016/483-c36-outcomes-for-patients-with-surgically-resected-thymic-neuroendocrine-tumors?format=html C36 – Outcomes for Patients with Surgically Resected Thymic Neuroendocrine Tumors Sceusi

]]> https://nanets.net/abstracts-archive/2016/483-c36-outcomes-for-patients-with-surgically-resected-thymic-neuroendocrine-tumors?format=html Sceusi

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:05:59 -0500 C34 – Number of Positive Nodes and Their Localization Correlate with Recurrence in Pancreatic Neuroendocrine Neoplasms: Implications for Surgery, Staging and Surveillance https://nanets.net/abstracts-archive/2016/481-c34-number-of-positive-nodes-and-their-localization-correlate-with-recurrence-in-pancreatic-neuroendocrine-neoplasms-implications-for-surgery-staging-and-surveillance?format=html C34 – Number of Positive Nodes and Their Localization Correlate with Recurrence in Pancreatic Neuroendocrine Neoplasms: Implications for Surgery, Staging and Surveillance Partelli

 Download Poster

]]> https://nanets.net/abstracts-archive/2016/481-c34-number-of-positive-nodes-and-their-localization-correlate-with-recurrence-in-pancreatic-neuroendocrine-neoplasms-implications-for-surgery-staging-and-surveillance?format=html Partelli

 Download Poster

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:05:58 -0500 C33 – Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-matched Analysis https://nanets.net/abstracts-archive/2016/480-c33-outcome-of-surgical-resection-after-neoadjuvant-peptide-receptor-radionuclide-therapy-prrt-for-pancreatic-neuroendocrine-neoplasms-a-case-matched-analysis?format=html C33 – Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-matched Analysis Partelli

 Download Poster

]]> https://nanets.net/abstracts-archive/2016/480-c33-outcome-of-surgical-resection-after-neoadjuvant-peptide-receptor-radionuclide-therapy-prrt-for-pancreatic-neuroendocrine-neoplasms-a-case-matched-analysis?format=html Partelli

 Download Poster

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:05:57 -0500 P16 – Association of Disease Progression, Health-related Quality of Life (HRQoL), and Utility in Patients with Advanced, Nonfunctional, Welldifferentiated Gastrointestinal (GI) or Lung Neuroendocrine Tumors (NET) in the Phase 3 RADIANT-4 Trial https://nanets.net/abstracts-archive/2016/479-p16-association-of-disease-progression-health-related-quality-of-life-hrqol-and-utility-in-patients-with-advanced-nonfunctional-welldifferentiated-gastrointestinal-gi-or-lung-neuroendocrine-tumors-net-in-the-phase-3-radiant-4-trial?format=html P16 – Association of Disease Progression, Health-related Quality of Life (HRQoL), and Utility in Patients with Advanced, Nonfunctional, Welldifferentiated Gastrointestinal (GI) or Lung Neuroendocrine Tumors (NET) in the Phase 3 RADIANT-4 Trial Singh

]]> https://nanets.net/abstracts-archive/2016/479-p16-association-of-disease-progression-health-related-quality-of-life-hrqol-and-utility-in-patients-with-advanced-nonfunctional-welldifferentiated-gastrointestinal-gi-or-lung-neuroendocrine-tumors-net-in-the-phase-3-radiant-4-trial?format=html Singh

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:04:43 -0500 P15 – Functional Status and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients https://nanets.net/abstracts-archive/2016/478-p15-functional-status-and-costs-of-care-during-the-first-year-after-diagnosis-of-neuroendocrine-tumors-among-elderly-patients?format=html P15 – Functional Status and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients Shen

]]> https://nanets.net/abstracts-archive/2016/478-p15-functional-status-and-costs-of-care-during-the-first-year-after-diagnosis-of-neuroendocrine-tumors-among-elderly-patients?format=html Shen

]]> support@adgcommunications.com (Super User) 2016 Thu, 15 Feb 2018 14:04:42 -0500